**Letrozole**

**Class:** Aromatase Inhibitor

**Indications:**

_Breast cancer

_Ovarian (unlabeled)

**Available dosage form in the hospital:**2.5 MG TAB

**Trade name :**Femara

**Doses:** Females: Postmenopausal:

-**Breast cancer, advanced (first- or second-line treatment):** Oral: 2.5 mg once daily; continue until tumor progression

-**Breast cancer, early (adjuvant treatment):** Oral: 2.5 mg once daily; optimal duration unknown, duration in clinical trial is 5 years; discontinue at relapse

-**Breast cancer, early (extended adjuvant treatment):** Oral: 2.5 mg once daily; optimal duration unknown, duration in clinical trials is 5 years (after 5 years of tamoxifen); discontinue at relapse

-**Ovarian (epithelial) cancer (unlabeled use):** Oral: 2.5 mg once daily; continue until disease progression.

**Geriatric**
Refer to adult dosing.

**Renal Impairment:**
No dosage adjustment is required in patients with renal impairment if $Cl_{cr}$ is ≥10 mL/minute.

**Hepatic Impairment:**
-Mild-to-moderate impairment (Child-Pugh class A or B): No adjustment recommended.
-Severe impairment (Child-Pugh class C) and cirrhosis: 2.5 mg every other day.

**Common side effect :**

Cardiovascular: Edema (7% to 18%)

Central nervous system: Headache (4% to 20%), dizziness (3% to 14%)

Endocrine & metabolic: Hypercholesterolemia (3% to 52%), hot flashes (6% to 50%)

Gastrointestinal: Nausea (9% to 17%), weight gain (2% to 13%), constipation (2% to 11%)

Neuromuscular & skeletal: Weakness (4% to 34%), arthralgia (8% to 25%), arthritis (7% to 25%), bone pain (5% to 22%), back pain (5% to 18%), bone mineral density decreased/osteoporosis (5% to 15%), bone fracture (10% to 14%)

Respiratory: Dyspnea (6% to 18%), cough (6% to 13%)

**Pregnancy category:** X